Port Jefferson, NY, United States of America

Iwao Ojima

This inventor holds 31 USPTO granted patents and 5 published patent applications and 5 EPO patents, primarily in Cancer Therapeutics. Top assignees: The State University of New York, Northeastern University, Targagenix, Inc.. Active years: 2001-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Iwao Ojima. Retrieved from https://idiyas.com/inventor/iwao-ojima

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 31 (Patent Applications = 5)

% Patents Active = 93.5

EPO Patents = 5 (Patent Applications = 9)

Average Co-Inventor Count = 2.1

ph-index = 4

Forward Citations = 151(Granted Patents)

Company Filing History:

30 out of 2,044

The State University of New York

patents

4 out of 686

Northeastern University

Chem-Master International, Inc.

patents

5. 1 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2025

Loading Chart...

Areas of Expertise:

Taxoid Nanoemulsions

Cancer Stem Cells

Matrix Metalloproteinase Inhibitors

Asymmetric Dendrimers

Benzimidazoles

Anti-fungal Compounds

Pharmaceutical Compositions

Tumor-targeting

Drug Conjugates

Sphingolipid Synthesis

Therapeutic Agents

Taxane Derivatives

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12325678 - Anti-fungals compounds targeting the synthesis of fungal sphingolipids (2025-06-10),

2. 12186428 - Combination taxoid nanoemulsion with immunotherapy in cancer (2025-01-07),

3. RE50096 - Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells (2024-08-27),

4. 12018003 - Substituted pyrimidines as matrix metalloproteinase-9 hemopexin domain inhibitors (2024-06-25),

5. 11858880 - Anti-fungals compounds targeting the synthesis of fungal sphingolipids (2024-01-02),

6. 11739047 - Alpha-truxillic acid derivatives and pharmaceutical compositions thereof (2023-08-29),

7. 11497713 - Combination taxoid nanoemulsion with immunotherapy in cancer (2022-11-15),

8. 11414378 - Anti-fungals compounds targeting the synthesis of fungal sphingolipids (2022-08-16),

9. 11040947 - Substituted quinazolines as matrix metalloproteinase-9 hemopexin domain inhibitors (2021-06-22),

10. 11026910 - α- and γ-truxillic acid derivatives and pharmaceutical compositions thereof (2021-06-08),

11. 10968163 - Alpha-truxillic acid derivatives and pharmaceutical compositions thereof (2021-04-06),

12. 10550093 - Third generation taxoids and methods of using same (2020-02-04),

13. 10280183 - Therapeutic agent for treating tumors (2019-05-07),

14. 10213406 - α- and γ-truxillic acid derivatives and pharmaceutical compositions thereof (2019-02-26),

15. 10206875 - Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells (2019-02-19),

Title: The Inventor Extraordinaire: Iwao Ojima

Introduction:

Meet Iwao Ojima, a prolific inventor based in Port Jefferson, NY, with an impressive track record of 27 patents to his name. His innovative work in the field of anti-fungal compounds and pharmaceutical compositions has made a significant impact in the scientific community.

Latest Patents:

Ojima's latest patents include groundbreaking inventions such as anti-fungal compounds targeting the synthesis of fungal sphingolipids, and Alpha-truxillic acid derivatives with pharmaceutical applications. These patents showcase his dedication to developing novel solutions for combating fungal infections and advancing the field of medicine.

Career Highlights:

Throughout his career, Ojima has made significant contributions to various research institutions, including The Research Foundation for the State University of New York and The Research Foundation of the State University of New York. His expertise and groundbreaking inventions have positioned him as a leading figure in the pharmaceutical and biotechnology industries.

Collaborations:

Ojima has collaborated with esteemed professionals in the field, including coworkers Dale Deutsch and Martin Kaczocha. These collaborations have not only enhanced his innovative work but have also paved the way for future research and development initiatives in the industry.

Conclusion:

In conclusion, Iwao Ojima's inventive prowess and dedication to scientific advancements have solidified his reputation as an inventor extraordinaire. His relentless pursuit of developing cutting-edge solutions in the realm of anti-fungal compounds and pharmaceutical compositions continues to inspire and drive innovation in the scientific community.

Profile summary based on public USPTO records.